px-12
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2006 (NCT00417287)
Timeline
Indications
Mechanism of action
- ThioredoxinINHIBITOR
TXN inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCC(C)SSc1ncc[nH]1- Mol. weight
- 188.32 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL406050 ↗
Also known as
- 1-methylpropyl 2-imidazolyl disulfide
- 1-methylpropyl 2-imidazolyl disulfide
- px-12
- px-12
- px-12
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00736372 | Phase 1 | Jun 1, 2008 | Cascadian Therapeutics Inc. |
| NCT00417287 | Phase 2 | Dec 1, 2006 | Cascadian Therapeutics Inc., National Cancer Institute (NCI) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cascadian Therapeutics Inc. | For profit | 2 | 2 | 2 | 2006 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2006 |
2 organizations
Page 1 / 1